SISC

Società Italiana per lo Studio delle Cefalee

SISC

Società Italiana per lo Studio delle Cefalee

Centro cefalee
Azienda Ospedaliero-Universitaria Careggi
Università degli Studi di Firenze

Centro Regionale
Direttore della struttura Prof. Pierangelo Geppetti
Prof. Federigo Sicuteri
Prof. Chiarugi Alberto
Dr. De Cesaris Francesco
Dr. Iannone Luigi Francesco
Altri componenti della struttura Dr. Andrea Burgalassi - Medico
Dr. Giulia Vigani

Patient Information

Location

  • Largo Brambilla 1
    50134 Firenze (FI)

Book an appointment

  • 055 545454 - Prime visite CUP Metropolitano
  • 055 794 2000 - Prenotazioni prestazioni in libera professione
Request times
Monday 08:00 - 18:00
Tuesday 08:00 - 18:00
Wednesday 08:00 - 18:00
Thursday 08:00 - 18:00
Friday 08:00 - 18:00

Clinic Hours

Operating hours for Outpatient visits
Monday 08:00 - 18:00
Tuesday 08:00 - 16:30
Wednesday 08:00 - 16:30
Thursday 08:00 - 18:00
Friday 08:00 - 16:30
Visita specialistica
Visita di controllo
Test farmacologici
Test genetici
Disassuefazione dagli analgesici
Attività informativa per il paziente
Altro: Prescrizione e somministrazione di tossina botulinica tipo A, Prescrizione e somministrazione anticorpi anti-CGRP
NO

Other Information

1200
890
NO
NO
Tossina botulinica
Altro: Somministrazione anticorpi monoclonali anti-CGRP
SI
SI
SI
SI
SI
Iannone LF., Burgalassi A., Vigani G., Tabasso G., De Cesaris F., Chiarugi A., Geppetti P. (2023) Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study. Cephalagia. 43(4)
Iannone, L.F., Fattori, D., Marangoni, M., Benemei S., Chiarugi A., Geppetti P., De Cesaris F. (2023) Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine. CNS Drugs
Iannone, L.F., Fattori, D., Marangoni, M., Benemei S., Chiarugi A., Geppetti P., De Cesaris F. (2023) Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine. CNS Drugs
Iannone LF., Burgalassi A., Vigani G., Tabasso G., De Cesaris F., Chiarugi A., Geppetti P. (2023) Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study. Cephalagia. 43(4)
De Logu, F., Landini, L., Janal, M.N., Li Puma, S., De Cesaris, F., Geppetti, P., Nassini, R. Migraine-provoking substances evoke periorbital allodynia in mice (2019) Journal of Headache and Pain, 20 (1) DOI: 10.1186/s10194-019-0968-1.
Muzzi, M., Zecchi, R., Ranieri, G., Urru, M., Tofani, L., De Cesaris, F., Panconesi, A., Chiarugi, A. Ultra-rapid brain uptake of subcutaneous sumatriptan in the rat: Implication for cluster headache treatment (2020) Cephalalgia, 40 (4) DOI: 10.1177/0333102419896370.
Lupi, C., Negro, A., Gambassi, E., Susini, T., Geppetti, P., Benemei, S. Medicines for headache before and during pregnancy: a retrospective cohort study (ATENA study) (2021) Neurological Sciences, 42 (5) DOI: 10.1007/s10072-020-047020.
Benemei, S., Lupi, C., De Cesaris, F., et al. Low-dose methadone for refractory chronic migraine accompanied by medication-overuse headache: a prospective cohort study (2021) Neurological Sciences DOI: 10.1007/s10072-020-04602-3.
Iannone, L.F., Geppetti, P., Chiarugi, A., De Cesaris, F. COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case report (2021) Internal and Emergency Medicine, 16 (8). DOI: 10.1007/s11739-021-02787-9.
Iannone L.F., Fattori D, Geppetti P, De Cesaris F. Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series. Neurol Sci. (2021). doi: 10.1007/s10072-021-05624-1.
Iannone, L.F., De Cesaris, F., Geppetti, P. Emerging Pharmacological Treatments for Migraine in the Pediatric Population (2022) Life, 12 (4), DOI: 10.3390/life12040536.
Iannone L.F., De Logu F., Geppetti P., De Cesaris F. The role of TRP ion channels in migraine and headache (2022) Neuroscience Letters, 768, 10.1016/j.neulet.2021.136380.
Iannone, L.F., Nassini, R., Patacchini, R., Geppetti, P., De Logu, F. Neuronal and non-neuronal TRPA1 as therapeutic targets for pain and headache relief (2022) Temperature DOI: 10.1080/23328940.2022.2075218.
Pistolesi, A., Buonvicino, D., Muzzi, M., Urru, M., Chiarugi, A. Effects of cluster headache preventatives on mouse hypothalamic transcriptional homeostasis (2022) Cephalalgia DOI: 10.1177/03331024221075613.
De Logu F, Nassini R, Hegron A, Landini L, Jensen DD, Latorre R, Ding J, Marini M, Monteiro de Araujo DS, Ramírez-Garcia P, Whittaker M, Retamal J, Titiz M, Innocenti A, Davis TP, Veldhuis N, Schmidt BL, Bunnett NW & Geppetti P, Schwann cell endosome CGRP signals elicit periorbital mechanical allodynia in mice. Nat Commun. 2022, 13(1):646.
Geppetti, P., De Cesaris, F., Benemei, S. et al. Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study (2022) Cephalalgia, DOI: 10.1177/03331024221093712.
Iannone L.F., Fattori D., Benemei S., Chiarugi A., Geppetti P., De Cesaris F. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients based on the MIDAS score (2022) CNS drugs DOI: 10.1007/s40263-021-00893-y.
Iannone LF, De Cesaris F, Ferrari A, Benemei S, Fattori D, Chiarugi A. Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine. Cephalalgia. July 2022. doi:10.1177/03331024221111526.
Iannone L.F., Fattori D., Benemei S., Chiarugi A., Geppetti P., De Cesaris F. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine (2022) European Journal of Neurology DOI: 10.1111/ene.15260.
Titolo protocollo Nome del comitato etico Numero di riferimento
Registro Italiano delle Cefalee (RiCe)
Phase 4 A REAL-world, retrospective cohort study of the prevention of episodic or chronic migraine in patients treated with galcanezumab at headache centres in ITalY: REALITY
Phase 4 Preventive Treatment of Migraine: Outcomes for Patients in Real-World Healthcare Systems, TRIUMPH study I5Q-MC-B004
Phase 4 Pan-European prospective observational study of fremanezumab effectiveness in patients with chronic or episodic migraine in the Real-World: PEARL study TV48125-MH-40146
Phase 3 Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache NCT04688775
Phase 3 Multicenter, Open-Label 52-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine NCT04686136
Phase 3 Multicenter, Randomized, Double-blind, Placebo controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Participants with Episodic Migraine Who Have Previously Failed 2 to 4 Classes of Oral Prophylactic Treatments (ELEVATE) NCT04740827
Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (Progress) NCT03855137
Phase 4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder” TEV-48125. NCT04041284
Phase 4 Randomized Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache NCT03971071
Luogo Data Congresso
Firenze 2023 Headache&CGRP
Firenze 2022 Headache&CGRP
Il centro ospita il past-president della SISC e due membri del centro studi SISC.

Not the Center you were looking for?

Search for another Migraine Center:

List of Migraine Centers in Toscana List of Migraine Centers near Firenze

Contact us
SISC - Società Italiana per lo Studio delle Cefalee
Registro Persone Giuridiche - Prefettura di Firenze - n. 534/2011
  • Address:
    Viale Pieraccini, 18
    50139 Firenze FI
    P.IVA 05057860487
    C.F. 01529430488
  • Phone: 075 585 8181 (dal lunedì al giovedì: orario: 8:30 - 13:00) Società Scientifica - non effettua visita per cefalee
  • Fax: 075 578 4229
  • Email: sisc@sisc.it
Search on site

Insert words to search and click on "Search" button

Newsletter SISC

Subscribe our newsletter to receive our news and updates

© 2014. SISC Società Italiana per lo Studio delle Cefalee. All rights reserved. Partita IVA 05057860487 - Codice Fiscale 01529430488
Privacy policy - Cookie policy - My consents